Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Yusri TahaHayley WardleAdam B EvansEwan R HunterHelen MarrWendy OsborneMatthew BashtonDarren SmithShirelle Burton-FanningMatthias L SchmidChristopher James Arthur DuncanPublished in: Annals of clinical microbiology and antimicrobials (2021)
These cases highlight the potential benefit of REGN-COV2 as therapy for persistent SARS-CoV-2 infection in antibody deficient individuals, including after failure of CP treatment. Formal clinical studies are warranted to assess the effectiveness of REGN-COV2 in antibody-deficient patients, especially in light of the emergence of variants of concern, such as Omicron, that appear to evade REGN-COV2 neutralisation.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- monoclonal antibody
- coronavirus disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- systematic review
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- replacement therapy
- copy number
- dna methylation
- mesenchymal stem cells
- genome wide
- bone marrow